The U.S. Food and Drug Administration last week sent a warning letter to a California manufacturer that has been marketing an injectable hemp CBD product to medical patients.
The letter, dated March 6, was sent to Sacramento-based Pico IV and asserts that its “intravenous form of cannabidiol” is an “unapproved new…
Please login to read all 313 words.
